Disclosures
None of the editors had any relevant financial relationships to disclose, unless noted.

Pharmaceutical use, investigational therapies, brand names, and manufacturers, if edits/writes may include discussion/reference to generic pharmaceuticals, off-label commercial products and/or services discussed in the CME activities.

Each of the editorial board members disclosed that the CME content he/she designed to ensure quality, objective, balanced, and scientifically rigorous AAP CME activities.

The American Academy of Pediatrics (AAP) Policy on Disclosure of Financial Statements and opinions expressed in Pediatrics in Review® are those of the author and are not necessarily those of the American Academy of Pediatrics or its Committees. Recommendations included in this publication do not indicate an exclusive course of treatment or serve as a standard of medical care. Subscription price for 2008 for print and online: $123/$93 for AAP Fellows, $153/$163 for AAP Candidate Fellows, $204/$227 for Nonmembers.

The confirmation of service of those in a position to influence and/or control CME content.

The AAP has taken steps to resolve any potential conflicts of interest: Dislosures

Richard Antaya, MD, FAAP, disclosed that he participates in the Antinea Pharma, US, Inc, speaker bureau advisory board, and is a Novartis speaker bureau advisor.

John Grima, MPH, FAAP, disclosed that he has research grants from Sanofigo Pharmaceuticals (Lubiprostone), Medtronic (Bravo pH Capsule), and TAP Pharmaceuticals (Prevacid), that he is on a Medtronics Advisory Board, and that he serves on a speaker bureau for TAP.

Howard Nissen, MD, FAAP, disclosed that he is a speaker for the committees of the American Academy of Pediatrics, and subsequently to learners whether the individual has relevant financial relationships with manufacturers of commercial products and/or services discussed in the CME activities.

Each of the editorial board members disclosed that the CME content he/she cites/data may include discussion/reference to generic pharmaceuticals, off-label pharmaceutical use, investigational therapies, brand names, and manufacturers, if appropriate.

None of the editors had any relevant financial relationships to disclose, unless noted below.

The AAP has taken steps to resolve any potential conflicts of interest: Dislosures

Richard Antaya, MD, FAAP, disclosed that he participates in the Antinea Pharma, US, Inc, speaker bureau advisory board, and is a Novartis speaker bureau advisor.

John Grima, MPH, FAAP, disclosed that he has research grants from Sanofigo Pharmaceuticals (Lubiprostone), Medtronic (Bravo pH Capsule), and TAP Pharmaceuticals (Prevacid), that he is on a Medtronics Advisory Board, and that he serves on a speaker bureau for TAP.

Howard Nissen, MD, FAAP, disclosed that he is a speaker for the committees of the American Academy of Pediatrics, and subsequently to learners whether the individual has relevant financial relationships with manufacturers of commercial products and/or services discussed in the CME activities.

Each of the editorial board members disclosed that the CME content he/she cites/data may include discussion/reference to generic pharmaceuticals, off-label pharmaceutical use, investigational therapies, brand names, and manufacturers, if appropriate.

None of the editors had any relevant financial relationships to disclose, unless noted below.

The AAP has taken steps to resolve any potential conflicts of interest: Dislosures

Richard Antaya, MD, FAAP, disclosed that he participates in the Antinea Pharma, US, Inc, speaker bureau advisory board, and is a Novartis speaker bureau advisor.

John Grima, MPH, FAAP, disclosed that he has research grants from Sanofigo Pharmaceuticals (Lubiprostone), Medtronic (Bravo pH Capsule), and TAP Pharmaceuticals (Prevacid), that he is on a Medtronics Advisory Board, and that he serves on a speaker bureau for TAP.

Howard Nissen, MD, FAAP, disclosed that he is a speaker for the committees of the American Academy of Pediatrics, and subsequently to learners whether the individual has relevant financial relationships with manufacturers of commercial products and/or services discussed in the CME activities.

Each of the editorial board members disclosed that the CME content he/she cites/data may include discussion/reference to generic pharmaceuticals, off-label pharmaceutical use, investigational therapies, brand names, and manufacturers, if appropriate.

None of the editors had any relevant financial relationships to disclose, unless noted below.

The AAP has taken steps to resolve any potential conflicts of interest: Dislosures

Richard Antaya, MD, FAAP, disclosed that he participates in the Antinea Pharma, US, Inc, speaker bureau advisory board, and is a Novartis speaker bureau advisor.

John Grima, MPH, FAAP, disclosed that he has research grants from Sanofigo Pharmaceuticals (Lubiprostone), Medtronic (Bravo pH Capsule), and TAP Pharmaceuticals (Prevacid), that he is on a Medtronics Advisory Board, and that he serves on a speaker bureau for TAP.
**Updated Information & Services**

including high resolution figures, can be found at:

http://pedsinreview.aappublications.org/content/29/11.citation

**Permissions & Licensing**

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:

https://shop.aap.org/licensing-permissions/

**Reprints**

Information about ordering reprints can be found online:

http://classic.pedsinreview.aappublications.org/content/reprints
29 (11)

Pediatrics in Review 2008;29;e59

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pedsinreview.aappublications.org/content/29/11.citation